AmberGen’s Photocleavable Linkers (PC-Linkers™)
Photocleavable Linkers (PC-Linkers™) use AmberGen’s fast and efficient 1-(2-nitrophenyl)ethyl nucleus, which yields >95% photocleavage efficiency in seconds to minutes using low-intensity near-UV light (e.g. 3-100 mW/cm2 @365 nm). This gentle photo-release, achieved without any harsh chemical conditions or additives, does not damage proteins or DNA. A key application is the isolation and photo-release of biomolecules for downstream use.
In one example, PC-Phosphoramidites can be coupled to the 5′ end of an oligonucleotide using standard chemistries. In the case of PC-Amino-Phosphoramidite, the free 5′ primary amine can then be reacted with any marker (M), which can be a solid surface (e.g. NHS activated beads) or another compound (e.g. standard NHS activated fluorophores and affinity tags). Photocleavage separates the marker from the oligonucleotide
AmberGen’s Protein Engineering Reagents
AmberGen has developed a novel class of proprietary Misaminoacylated tRNAs, in particular, capable of incorporating fluorescent and/or photocleavable biotin (PC-Biotin) labeled amino acids, both at the N-terminus or randomly throughout the peptide chain, using prokaryotic or eukaryotic expression systems (including mammalian). AmberGen licenses one such tRNA, FluoroTect™ GreenLys, to Promega Corporation. Moreover, as reported by Iborra et al. in Science, this tRNA has also proven useful in permeabilized mammalian cells for basic research applications.
Use of AmberGen’s Proprietary tRNAs in Protein Engineering Technologies: Misaminoacylated tRNAs are used to co-translationally incorporate labeled amino acids (e.g. bearing a fluorophore or a PC-Biotin) selectively into the target protein during its in vitro translation.
Licensing & Distribution
AmberGen has licensed and/or distributed its products through leading companies in the Life Sciences field
Trademarks: Promega, Thermo-Fisher, INOVA Diagnostics, SomaLogic and the accompanying logos are registered Trademarks of Promega Corporation, Madison, WI; Thermo Fisher Scientific, Inc., Waltham, MA; INOVA Diagnostics, Inc., San Diego, CA; and SomaLogic, Inc., Boulder, CO, respectively.
